Black patients more likely to be diagnosed with late stage lung cancer, regardless of income, education level
Black Americans living in areas with the highest income and education levels were still more likely than white patients in the lowest education and income areas to have advanced-stage lung ..... see more
Blood-based biomarker can predict the benefit of immunotherapy to lung cancer patients
A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine. The findings from this study ..... see more
BioMark Diagnostics Raises C$1.5M to Commercialize Lung Cancer Liquid Biopsy Test
NEW YORK - Liquid biopsy firm BioMark Diagnostics said Wednesday that it has raised C$1.5 million (US$1.2 million) through a private financing round and new line of credit to help ..... see more
A Year of Lung Cancer Improvements, With More Work To Do
This transcript has been edited for clarity. This is Mark Kris from Memorial Sloan Kettering, commenting today on the annual release of cancer statistics by Rebecca L. Siegel, MPH, and ..... see more
Giving immunotherapy before surgery prevents lung cancer from returning, study says
iving the immunotherapy Opdivo, made by Bristol Myers Squibb, to lung cancer patients before surgery can help prevent the disease from coming back, a new study says. It's a step ..... see more
Source : https://www.statnews.com/2022/04/11/opdivo-lung-cancer-surgery/
Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%
Merck's antibody therapy for early stage lung cancer patients who have previously undergone surgery to have tumors removed reduced the risk of the disease returning again or the patient dying ..... see more
Immunotherapy Co-Opts Physically Interacting Cells in Lung Tumors
A new study defines a key subset of T cells in the microenvironment of human lung cancer that physically interact and directly communicate with antigen presenting dendritic cells to protect ..... see more
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer1 In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy significantly improved event-free survival ..... see more
FDA grants priority review to Opdivo for non-small cell lung cancer indication
The FDA granted priority review to nivolumab for use with chemotherapy as neoadjuvant treatment of patients with resectable non-small cell lung cancer.Nivolumab (Opdivo, Bristol Myers Squibb), a PD-1 immune checkpoint ..... see more
Surprise Discovery Suggests New Treatment for Small-Cell Lung Cancer
An unexpected discovery at UVA Cancer Center has allowed scientists to halt the development of small-cell lung cancer in lab mice, and the surprise finding could open the door to ..... see more
Linnea Olson: An Appreciation
Linnea Olson, a cancer activist, artist and blogger, who has lived with advanced lung cancer for 14 years, helps teach audiences about the patient experience in our executive education programs. ..... see more
Source : https://executiveeducation.hms.harvard.edu/linnea-olson-appreciation
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma - PubMed
Severe immune-related adverse events (irAEs) occur in up to 60% of patients with melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether a common baseline immunological state ..... see more
HLA-independent T cell receptors for targeting tumors with low antigen density - Nature Medicine
HLA-independent T cell receptors, in which the heavy and light chains of a chimeric antigen receptor are incorporated into the endogenous T cell receptor locus, are more effective than CD28-based ..... see more
"Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor–CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR....
Cancer mortality rates continue to decline amid 'major progress' in lung cancer early detection and treatment
Cancer mortality rates have been dropping for nearly two decades, aided by "major progress" in the early detection and treatment options for lung cancer, according to the American Cancer Society's ..... see more
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study - PubMed
doi: 10.1200/JCO.21.01874. Online ahead of print. 1 Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, OH. 2 Department of Medical ..... see more
The renal clear cell carcinoma immune landscape
A comprehensive evaluation of the clear cell renal cell carcinoma (ccRCC) immune landscape was found using 584 RNA-sequencing datasets from The Cancer Genome Atlas (TCGA), we identified 17 key dysregulated ..... see more
Source : https://www.sciencedirect.com/science/article/pii/S1476558621001111?via=ihub
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC - PubMed
doi: 10.1016/j.lungcan.2021.12.014. Online ahead of print. 1 Medical Oncology, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. ..... see more
Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period - PubMed
The first-line treatment of SCLC patients admitted to our hospital in the past 8 years was relatively standardized, and the progression-free survival and OS were slightly longer than those reported ..... see more
Conclusions: The first-line treatment of SCLC patients admitted to our hospital in the past 8 years was relatively standardized, and the progression-free survival and OS were slightly longer than those reported in the literature. We developed a prognostic risk score model for extensive-stage SCLC to calculate individual survival in clinical...